Sacklers could hold on to most of personal fortune in proposed Purdue settlement

Under a novel plan to relinquish control of Purdue Pharma and resurrect it as a trust whose main purpose would be to combat the opioid epidemic, the Sacklers could raise most, if not all, of their personal share of the recent $10-$12billion settlement by selling their international drug conglomerate, Mundipharma.